Clinical trials: Chronic Obstructive Pulmonary Diseases
Asthma
Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS in systemic corticosteroid dependent patients with severe refractory asthma with elevated eosinophils.
- Trial name
- NCT02075255
- Testing
- Benralizumab
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
COPD, Pulmonary Hypertension
Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen
The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of long term iNO administrationusing the…
- Conditions
- COPD, Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT03135860
- Testing
- Inhaled Nitric Oxide 30mcg/kg IBW/hr
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Bellerophon
Chronic Obstructive Pulmonary Disease, Non-cystic Fibrosis Bronchiectasis
A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life
This study aims to evaluate the impact of a specific oral probiotic blend on the quality of life of adults with respiratory conditions.
- Trial name
- NCT05523180
- Testing
- Probiotic
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- ResBiotic Nutrition, Inc.
Respiratory Tract Infections, Chronic Bronchitis
KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections
The purpose of this study is to determine if 1 course of antibiotic treatment with telithromycin is superior to azithromycin in the treatment of lower respiratory tract infections (LRTIs), acute exacerbations of chronic…
- Conditions
- Respiratory Tract Infections, Chronic Bronchitis, Pneumonia
- Trial name
- KEYS (NCT00132951)
- Testing
- Telithromycin, Azithromycin
- Where
- 2 sites in United States, Canada
- Volunteers
- 2,051 people
- Sponsor
- Sanofi
Asthma
Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma
Evaluate the safety and tolerability of a single dose of S-1226 (8%) in subjects with mild atopic asthma.
- Trial name
- S-1226(8%) (NCT02334553)
- Testing
- S1226(8%)
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- SolAeroMed Inc.
COPD
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
- Trial name
- GOLDEN 6 (NCT02038829)
- Testing
- SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sunovion Respiratory Development Inc.
Anemia, Diabetes, Kidney Disease, Chronic, Hypertension
Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan
The purpose of this study is to evaluate the prevalence of CKD-related anemia at an early stage through screening of high-risk patients in Pakistan at the level of physicians, cardiologists, and diabetologists.
- Trial name
- NCT02444845
- Where
- 3 sites in Pakistan
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to evaluate the lung function response to the free once-daily combination of tiotropium + formoterol compared to formoterol BID and tiotropium QD
- Trial name
- NCT02238119
- Testing
- Tiotropium + formoterol combination, Tiotropium, Formoterol
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD) Breathing Record Study
This study is being done to collect information that will be used in the development of a new medical device. The new device is intended to help people with COPD to monitor their condition at home on a daily basis.
- Trial name
- CBRS (NCT02814253)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- TidalSense
COPD
Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD
This is a phase 1/phase 2a, single dose, crossover study conducted in two parts. Part 1: Phase 1, open-label, 4-period crossover study in 8 healthy subjects to determine the optimal dose of AERO-001 and AERO-002, the active…
- Trial name
- NCT06841640
- Testing
- AERO-001, AERO-002, AERO-007
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AeroRx Therapeutics Inc.
COPD
Nasal High Flow (NHF) in COPD - Effects on Ventilation in Wakefulness
Controlled randomized crossover trial in patients with chronic obstructive respiratory disease (COPD), who are treated with Nasal High Flow (NHF) therapy during wakefulness with a small amount of CO2 added to the inhaled air to…
- Trial name
- NCT05053074
- Testing
- Nasal High Flow (NHF)
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Chronic Obstructive Pulmonary Disease (COPD)
Sodium Pyruvate Therapy in COPD Patients
In animal models, sodium pyruvate has been shown to be an effective anti-inflammatory agent, and in human studies sodium pyruvate has been shown to be a bronchodilating agent.
- Trial name
- NCT00262613
- Testing
- sodium pyruvate in 0.9% sodium chloride solution
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emphycorp
Pulmonary Disease, Chronic Obstructive
A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD
This is a 24-week, phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The study will have 9 scheduled visits and a telephone contact Follow-up visit one week following the end of study…
- Trial name
- NCT01636713
- Testing
- GSK573719/VI 62.5/25, GSK573719/VI 125/25
- Where
- 44 sites in China, Philippines and 3 more
- Volunteers
- 581 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, COPD
Study to Assess the Effect of the Aerobika Device in Addition to Standard of Care Treatment in Sputum Producing COPD Patients Using FRI
Primary: The primary objective of this study is to evaluate the effect of the Aerobika® device on the aerosol deposition pattern of concomitant inhalation medication using FRI.
- Trial name
- NCT02936817
- Testing
- Aerobika® Device, HRCT scans
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- FLUIDDA nv
Pulmonary Disease, Chronic Obstructive
Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease
Primary objective: To investigate bronchodilator effect and safety of single doses of BI 1744 CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics of BI 1744 CL.
- Trial name
- NCT01809262
- Testing
- single dose of 5 mcg, single dose of 40 mcg, single dose of 20 mcg
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
COPD
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium…
- Trial name
- NCT03937479
- Where
- 50 sites in United States
- Volunteers
- 416 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Kidney Diseases, Chronic Renal Insufficiency
Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
Approximately 207 patients with chronic kidney disease (CKD) on hemodialysis will be entered into this study at approximately 26 centers in the United States.
- Conditions
- Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
- Trial name
- NCT00268957
- Testing
- Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®)
- Where
- 29 sites in United States
- Volunteers
- 217 people
- Sponsor
- Genzyme, a Sanofi Company
COPD
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.
- Trial name
- NCT02465567
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg
- Where
- 741 sites in United States, Argentina and 24 more
- Volunteers
- 8,588 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
- Trial name
- GLOW 1 (NCT01005901)
- Testing
- Glycopyrronium bromide
- Where
- 96 sites in United States, Australia and 9 more
- Volunteers
- 1,324 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol (in terms of the spirometry assessment forced expiratory volume in 1 second [FEV1]) over the full 24-h time period
- Trial name
- NCT00615030
- Testing
- Indacaterol, Salmeterol
- Where
- 7 sites in France, Germany and 1 more
- Volunteers
- 96 people
- Sponsor
- Novartis